Vertex Pharmaceuticals IncNASDAQ:VRTX
- LAST PRICE473.7800
- TODAY'S CHANGE (%)2.5300 (0.5369%)
- Bid / Lots470.0000/ 4
- Ask / Lots479.0000/ 5
- Open / Previous Close469.7600 / 471.2500
- Day Range
- 52 Week Range
- Volume825,065
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VRTX |
|---|---|---|
| 09:32 ET | 9176 | 471.75 |
| 09:34 ET | 1030 | 469.32 |
| 09:36 ET | 550 | 469.645 |
| 09:38 ET | 1893 | 468.83 |
| 09:39 ET | 900 | 469.56 |
| 09:41 ET | 500 | 469.615 |
| 09:43 ET | 700 | 469.13 |
| 09:45 ET | 1445 | 469.33 |
| 09:48 ET | 1103 | 467.95 |
| 09:50 ET | 203 | 468.0626 |
| 09:52 ET | 400 | 468.2 |
| 09:54 ET | 500 | 467.98 |
| 09:56 ET | 1461 | 467.435 |
| 09:57 ET | 400 | 467.565 |
| 09:59 ET | 1880 | 468.06 |
| 10:01 ET | 1500 | 469.23 |
| 10:03 ET | 1608 | 469.365 |
| 10:06 ET | 876 | 469.82 |
| 10:08 ET | 1225 | 469.95 |
| 10:10 ET | 800 | 470.415 |
| 10:12 ET | 791 | 470.28 |
| 10:14 ET | 485 | 470.5601 |
| 10:15 ET | 2600 | 471.67 |
| 10:17 ET | 1218 | 470.53 |
| 10:19 ET | 156 | 470.675 |
| 10:21 ET | 1400 | 470.735 |
| 10:24 ET | 763 | 471.51 |
| 10:28 ET | 400 | 471.446 |
| 10:30 ET | 350 | 471.46 |
| 10:32 ET | 260 | 471.64 |
| 10:33 ET | 907 | 471.77 |
| 10:35 ET | 900 | 472.735 |
| 10:37 ET | 3199 | 473.14 |
| 10:39 ET | 400 | 473.745 |
| 10:42 ET | 1349 | 474.01 |
| 10:44 ET | 2769 | 474.67 |
| 10:46 ET | 2000 | 473.78 |
| 10:48 ET | 500 | 473.585 |
| 10:50 ET | 400 | 473.825 |
| 10:51 ET | 1696 | 474.525 |
| 10:53 ET | 1059 | 474.64 |
| 10:55 ET | 2646 | 475.48 |
| 10:57 ET | 3379 | 475.95 |
| 11:00 ET | 2039 | 476.13 |
| 11:02 ET | 831 | 476.3843 |
| 11:04 ET | 2752 | 476.18 |
| 11:06 ET | 400 | 475.785 |
| 11:08 ET | 908 | 476.47 |
| 11:09 ET | 900 | 476.61 |
| 11:11 ET | 8090 | 476.0698 |
| 11:13 ET | 7151 | 475.345 |
| 11:15 ET | 1856 | 476.505 |
| 11:18 ET | 1092 | 476.555 |
| 11:20 ET | 605 | 476.515 |
| 11:22 ET | 300 | 476.23 |
| 11:24 ET | 400 | 476.62 |
| 11:26 ET | 500 | 476.665 |
| 11:27 ET | 304 | 476.665 |
| 11:29 ET | 5963 | 477.56 |
| 11:31 ET | 1085 | 477.405 |
| 11:33 ET | 1312 | 477 |
| 11:36 ET | 100 | 476.935 |
| 11:38 ET | 100 | 476.95 |
| 11:40 ET | 1001 | 477.195 |
| 11:42 ET | 742 | 476.85 |
| 11:44 ET | 525 | 476.9 |
| 11:45 ET | 944 | 476.79 |
| 11:47 ET | 125 | 476.36 |
| 11:49 ET | 1711 | 476.1025 |
| 11:51 ET | 1754 | 476.445 |
| 11:54 ET | 200 | 476.84 |
| 11:56 ET | 1809 | 475.75 |
| 11:58 ET | 1559 | 475.71 |
| 12:00 ET | 200 | 475.87 |
| 12:02 ET | 1133 | 475.515 |
| 12:03 ET | 1100 | 475.28 |
| 12:09 ET | 433 | 476.04 |
| 12:12 ET | 600 | 475.53 |
| 12:14 ET | 641 | 475.27 |
| 12:16 ET | 200 | 475.52 |
| 12:20 ET | 100 | 475.62 |
| 12:21 ET | 1212 | 475.3 |
| 12:25 ET | 200 | 475.16 |
| 12:27 ET | 300 | 475.7092 |
| 12:30 ET | 301 | 475.98 |
| 12:32 ET | 1560 | 475.64 |
| 12:34 ET | 808 | 475.17 |
| 12:36 ET | 1811 | 474.715 |
| 12:38 ET | 508 | 474.71 |
| 12:39 ET | 1129 | 474.7025 |
| 12:41 ET | 802 | 474.65 |
| 12:43 ET | 1393 | 474.3855 |
| 12:45 ET | 600 | 474.1701 |
| 12:48 ET | 100 | 474.38 |
| 12:50 ET | 1000 | 474.42 |
| 12:52 ET | 960 | 474.335 |
| 12:54 ET | 2350 | 474.1799 |
| 12:56 ET | 300 | 473.835 |
| 12:57 ET | 401 | 473.76 |
| 12:59 ET | 715 | 473.89 |
| 01:01 ET | 858 | 473.39 |
| 01:03 ET | 551 | 472.98 |
| 01:06 ET | 820 | 473.28 |
| 01:08 ET | 456 | 473.425 |
| 01:10 ET | 1000 | 473.185 |
| 01:12 ET | 300 | 472.92 |
| 01:14 ET | 700 | 473.08 |
| 01:15 ET | 963 | 473.24 |
| 01:17 ET | 976 | 473.06 |
| 01:19 ET | 925 | 473.43 |
| 01:21 ET | 784 | 473.01 |
| 01:24 ET | 807 | 473.19 |
| 01:26 ET | 200 | 473.0275 |
| 01:28 ET | 200 | 472.91 |
| 01:30 ET | 200 | 472.6 |
| 01:32 ET | 1800 | 472.7 |
| 01:33 ET | 711 | 473.02 |
| 01:35 ET | 245 | 472.99 |
| 01:37 ET | 1079 | 473.425 |
| 01:39 ET | 1526 | 473.475 |
| 01:44 ET | 290 | 473.425 |
| 01:46 ET | 252 | 473.39 |
| 01:48 ET | 100 | 473.24 |
| 01:50 ET | 279 | 473.15 |
| 01:51 ET | 200 | 473.29 |
| 01:53 ET | 283 | 473.53 |
| 01:55 ET | 300 | 473.79 |
| 01:57 ET | 456 | 473.77 |
| 02:00 ET | 1294 | 473.54 |
| 02:02 ET | 300 | 473.7 |
| 02:04 ET | 300 | 474 |
| 02:06 ET | 793 | 474.06 |
| 02:08 ET | 271 | 474.23 |
| 02:09 ET | 500 | 474.17 |
| 02:11 ET | 700 | 473.995 |
| 02:13 ET | 491 | 473.975 |
| 02:15 ET | 1656 | 473.97 |
| 02:20 ET | 413 | 474.005 |
| 02:22 ET | 1080 | 474.35 |
| 02:24 ET | 1603 | 474.38 |
| 02:26 ET | 475 | 474.26 |
| 02:27 ET | 300 | 474.56 |
| 02:29 ET | 800 | 474.68 |
| 02:31 ET | 1514 | 474.755 |
| 02:36 ET | 1491 | 475.305 |
| 02:38 ET | 1250 | 475.43 |
| 02:40 ET | 600 | 475.8 |
| 02:42 ET | 1733 | 475.15 |
| 02:44 ET | 1357 | 475.19 |
| 02:45 ET | 200 | 475.285 |
| 02:47 ET | 601 | 475.36 |
| 02:49 ET | 1000 | 475.09 |
| 02:51 ET | 1164 | 475.4 |
| 02:54 ET | 481 | 475.26 |
| 02:56 ET | 800 | 475.08 |
| 02:58 ET | 460 | 475.275 |
| 03:00 ET | 900 | 474.99 |
| 03:02 ET | 620 | 474.93 |
| 03:03 ET | 3212 | 474.98 |
| 03:05 ET | 400 | 475 |
| 03:07 ET | 300 | 475.15 |
| 03:09 ET | 1865 | 474.84 |
| 03:12 ET | 908 | 474.36 |
| 03:14 ET | 800 | 474.48 |
| 03:16 ET | 300 | 474.16 |
| 03:18 ET | 400 | 474.4 |
| 03:20 ET | 1590 | 474.23 |
| 03:21 ET | 1242 | 474 |
| 03:23 ET | 1800 | 473.79 |
| 03:25 ET | 200 | 473.75 |
| 03:27 ET | 600 | 474.02 |
| 03:30 ET | 1035 | 474.11 |
| 03:32 ET | 729 | 474.0809 |
| 03:34 ET | 1730 | 474.17 |
| 03:36 ET | 720 | 474.045 |
| 03:38 ET | 1400 | 474.15 |
| 03:39 ET | 2617 | 474.125 |
| 03:41 ET | 1306 | 474.2 |
| 03:43 ET | 1641 | 474.44 |
| 03:45 ET | 1824 | 474.235 |
| 03:48 ET | 1500 | 474.17 |
| 03:50 ET | 1127 | 474.335 |
| 03:52 ET | 3160 | 474.2 |
| 03:54 ET | 2716 | 474.545 |
| 03:56 ET | 11330 | 473.87 |
| 03:57 ET | 7177 | 473.98 |
| 03:59 ET | 10010 | 473.78 |
Today
DJ Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis, from 9 hours ago by Dow Jones
9 hours ago by Dow Jones
Yesterday
Press Release: Vertex to Announce Second Quarter 2024 Financial Results on August 1, from 4:20PM ET on Monday Jul 01, 2024 by Dow Jones
4:20PM ET on Monday Jul 01, 2024 by Dow JonesVertex to Announce Second Quarter 2024 Financial Results on August 1, from 4:05PM ET on Monday Jul 01, 2024 by Dow Jones
4:05PM ET on Monday Jul 01, 2024 by Dow Jones
Jun 27, 2024
DJ Vertex Pharmaceuticals Initiated at Buy by Redburn Atlantic, from 5:57AM ET on Thursday Jun 27, 2024 by Dow Jones
5:57AM ET on Thursday Jun 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vertex Pharmaceuticals Inc | 121.6B | 30.7x | +46.35% |
Regeneron Pharmaceuticals Inc | 116.5B | 30.9x | +10.93% |
Biogen Inc | 33.7B | 28.6x | -18.14% |
Moderna Inc | 44.4B | -7.5x | --- |
ICON PLC | 26.2B | 38.6x | +4.68% |
IQVIA Holdings Inc | 38.0B | 28.3x | +46.62% |
Company Information
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Contact Information
- Headquarters
- 50 Northern AvenueBOSTON, MA, United States 02210
- Phone
- 617-341-6393
- Fax
- ---
Executives
- Executive Chairman of the Board
- Jeffrey Leiden
- President, Chief Executive Officer, Director
- Reshma Kewalramani
- Chief Financial Officer, Executive Vice President
- Charles Wagner
- Chief Operating Officer, Executive Vice President
- Stuart Arbuckle
- Executive Vice President - Global Research, Chief Scientific Officer
- David Altshuler
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $121.6B |
|---|---|
Revenue (TTM) | $10.2B |
Shares Outstanding | 258.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $15.42 |
Book Value | $68.22 |
P/E Ratio | 30.7x |
Price/Sales (TTM) | 11.9 |
Price/Cash Flow (TTM) | 28.8x |
Operating Margin | 41.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
